Form 4: CareDx Officer Plans Stock Sale Under 10b5-1 Plan

CareDx's Secretary and General Counsel, Jeffrey Adam Novack, plans to sell 2,688 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Jeffrey Adam Novack, Secretary and General Counsel of CareDx, Inc. (CDNA), filed a Form 4 disclosing a planned sale of 2,688 shares of common stock.
• The transaction is scheduled for August 5, 2025, and will be executed pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2024.
• The shares are planned to be sold at a weighted average price of $12.7904 per share, with individual sales ranging from $12.33 to $13.03.
• Following this planned transaction, Mr. Novack will beneficially own 112,930 shares of CareDx common stock directly.

Sentiment

Score: 5

Explanation: The filing details a pre-scheduled, future stock sale by an officer under a 10b5-1 plan. Such transactions are routine and generally do not reflect new material information or a change in the insider's view of the company's prospects, thus having a neutral impact on sentiment.

Negatives

• The planned sale by an insider, even under a 10b5-1 plan, represents a reduction in direct ownership by a key executive.

Future Outlook

The filing details a future planned transaction under a pre-arranged trading plan, but does not provide any forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This filing is a routine disclosure of an insider's planned stock transaction and does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• The sale of common stock by Jeffrey Adam Novack, an officer of CareDx, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, which is generally not significant given the pre-planned nature of the sale and the remaining beneficial ownership.

Key Dates

Recommendation

The filing is a routine disclosure of a pre-scheduled future stock sale by an officer under a 10b5-1 plan. It does not provide new material information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation.

Keywords

CareDx, CDNA, Form 4, Insider Trading, Stock Sale, Jeffrey Adam Novack, 10b5-1 Plan, Corporate Officer